Investor Alert: BioAge Labs Faces Class Action Over Securities Fraud Allegations

Introduction
In an alarming development for investors, BioAge Labs, Inc. (NASDAQ: BIOA) is currently embroiled in a class action lawsuit concerning potential securities fraud. The notice, which comes from the law firm Levi & Korsinsky, LLP, is directed at BioAge shareholders who purchased stock during the initial public offering (IPO) that took place on September 26, 2024. Investors are advised to take action before the court deadline of March 10, 2025.

Background on the Lawsuit

The class action lawsuit aims to address losses incurred by shareholders who may have been negatively impacted by BioAge’s alleged misrepresentation of critical information concerning the company’s lead product candidate. Specifically, the lawsuit relates to claims that BioAge provided misleading information regarding the safety and efficacy of azelaprag, leading investors to make purchases under false pretenses.

On December 6, 2024, BioAge announced a shocking decision to discontinue its STRIDES Phase 2 clinical trial for azelaprag due to safety concerns linked to elevated liver enzymes in patients. This revelation contradicted earlier assertions made during its IPO, where the company emphasized azelaprag's potential benefits for patients on obesity therapy.

Market Reaction

The disclosure had a dramatic impact on BioAge's stock price, which plummeted from $20.09 per share on December 6 to just $4.65 the following day, prompting outrage among investors who felt misled. The sharp decline highlighted the risks investors faced based on the communicated assurances regarding the safety of bio-pharmaceutical products.

Your Rights as an Investor

Investors who acquired shares during the relevant period have until March 10, 2025, to seek appointment as lead plaintiff in this litigation. However, it is crucial to note that participation in the lawsuit does not mandate you to be a lead plaintiff to potentially benefit from any recovery that may arise from the case.

Levi & Korsinsky assures that there are no costs or fees incurred by class members. Eligible individuals can pursue compensation without facing any out-of-pocket expenses, further emphasizing the law firm’s commitment to shareholder rights.

How to Get Involved

For investors who believe they have been affected by the actions of BioAge Labs, it's pivotal to act promptly. You may reach out to Levi & Korsinsky by contacting attorney Joseph E. Levi at the listed email or phone number for more information and to discuss your rights in this case. Find more details here.

The Reputation of Levi & Korsinsky

With two decades of experience, Levi & Korsinsky has established itself as a formidable force in securities litigation, recovering hundreds of millions of dollars for distressed shareholders. The law firm is consistently recognized in leading rankings for its success in handling high-stakes securities cases. Their expertise offers investors a much-required reassurance amid the current turmoil surrounding BioAge Labs.

Conclusion

BioAge Labs, Inc. stands at a critical juncture as it faces serious allegations that could significantly affect its investors and overall market perception. If you are among those adversely impacted by this situation, ensuring your voice is heard before the March deadline is crucial. The ongoing developments in this case will be closely watched by both investors and industry observers alike.

For more information or assistance regarding your potential claims, please contact Levi & Korsinsky using the details provided above.